Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24862786 | 0.89 | CNR1 (0.31) | HDAC8 | |
| SCHEMBL21191752 | 0.85 | CNR2 (0.38) | — | |
| SCHEMBL25627108 | 0.84 | HDAC8 (0.32) | HDAC8 | |
| SCHEMBL23634131 | 0.83 | HDAC8 (0.34) | HDAC8 | |
| SCHEMBL15979325 | 0.81 | ALOX5 (0.30) | HDAC8 | |
| SCHEMBL6976768 | 0.78 | TAAR1 (0.34) | HDAC8 | |
| SCHEMBL19475260 | 0.78 | HDAC8 (0.33) | HDAC8 | |
| SCHEMBL21398067 | 0.77 | HDAC8 (0.30) | HDAC8 | |
| SCHEMBL22020866 | 0.76 | — | — | |
| SCHEMBL20809950 | 0.75 | TAAR1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3979384-A1 | ELECTROLYTE FOR LITHIUM ION BATTERY, LITHIUM ION BATTERY, BATTERY MODULE, BATTERY PACK AND DEVICE | Contemporary Amperex Technology Co., Limited (CN) | 2022-04-06 | — | — | EP | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-10675286-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| WO-2019178191-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-10329299-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180044346-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-9828377-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675286-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | HDAC8 397/4885 |
| US-10329299-B2 | Heterocyclic compounds and uses thereof | PIK3CA, AKT1, AKT2 | HDAC8 314/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | HDAC8 1744/4885 |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | HDAC8 397/4885 |
| US-20180044346-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | HDAC8 397/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | HDAC8 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.